# ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)

> **NCT05601752** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **USWM CT, LLC** · enrollment: 66 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **GENETIC:** Autologous genetically modified ADP-A2M4CD8 cells
- **COMBINATION_PRODUCT:** Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab

## Key facts

- **NCT ID:** NCT05601752
- **Lead sponsor:** USWM CT, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-26
- **Primary completion:** 2026-08-12
- **Final completion:** 2026-08-12
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-02-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05601752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05601752, "ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05601752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*